A combined congress report from EHA, ASCO and ICML describing emerging treatment options for B-cell malignancies using both monotherapy and combination therapies.

Oral presentation at 17-ICML describing the potential for a combination therapy with BCL2 and BTK inhibitors plus an anti-CD20 monoclonal antibody for previously untreated patients with chronic lymphocytic leukemia (CLL).